"Designing Growth Strategies is in our DNA"

Pharmacovigilance Market Size, Share & Industry Analysis, By Type (Service and Software), By Deployment (In-house and Outsource), By End-User (Contract Research Organizations (CROs), Pharmaceutical & Biotechnfology Companies, and Others), and Regional Forecast, 2024-2032

Last Updated: January 20, 2025 | Format: PDF | Report ID: FBI102746

 


To get information on various segments, share your queries with us

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2022

Growth Rate

CAGR of 13.8% from 2024-2032

Unit

Value (USD Billion)

Segmentation

By Type

  • Service
  • Software

By Deployment 

  • In-house
  •  Outsource

By End User

  • Contract Research Organizations (CROs)
  • Pharmaceutical & Biotechnology Companies
  • Others

By Region

  • North America (By Type, Deployment, End-User, and Country)
    • U.S. (By Type)
    • Canada (By Type)
  • Europe (By Type, Deployment, End-User, and Country/Sub-Region)
    • Germany (By Type)
    • U.K. (By Type)
    • France (By Type)
    • Italy (By Type)
    • Spain (By Type)
    • Rest of Europe (By Type)
  • Asia Pacific (By Type, Deployment, End-User, and Country/Sub-Region)
    • China (By Type)
    • Japan (By Type)
    • India (By Type)
    • Australia (By Type)
    • Southeast Asia (By Type)
    • Rest of Asia Pacific (By Type)
  • Latin America (By Type, Deployment, End-User, and Country/Sub-Region)
    • Brazil (By Type)
    • Mexico (By Type)
    • Rest of Latin America (By Type)
  • Middle East & Africa (By Type, Deployment, End-User, and Country/Sub-Region)
    • GCC (By Type)
    • South Africa (By Type)Rest of the Middle East & Africa (By Type)
  • 2019-2032
  • 2023
  • 2019-2022
  • 149
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X